AnaptysBio, Inc. (ANAB) key performance indicators and operating metrics (5 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Collaboration Revenue | 25.6M | FY2026-Q1 |
| Jemperli Royalties | 24.7M | FY2026-Q1 |
| Jemperli Revenue | 303M | FY2025-Q3 |
| Advanced Therapy Experienced Percentage in Ulcerative Colitis Phase 2 Trial | 50.00 percent | FY2025-Q3 |
| Number of Patients in Ulcerative Colitis Phase 2 Trial | 136.00 | FY2025-Q3 |
Back to ANAB overview · ANAB earnings · ANAB holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.